$GANX News

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract

Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders

Gain Therapeutics Appoints CEO Gene Mack As Interim CFO, Effective Oct. 1, Succeeding Principal Financial Officer Gianluca Fuggetta

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Why Is GANX Stock Rallying 22% After Hours?

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit